Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction
Authors:
- 1 February 2003
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 145 (2) , 217-225
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Pharmacokinetics and Pharmacodynamics of Tenecteplase: Results from a Phase II Study in Patients with Acute Myocardial InfarctionThe Journal of Clinical Pharmacology, 2000
- Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trialAmerican Heart Journal, 1999
- TNK-Tissue Plasminogen Activator in Acute Myocardial InfarctionCirculation, 1997
- Differences in clot lysis among patients demonstrated in vitro with three thrombolytic agents (tissue-type plasminogen activator, streptokinase and urokinase)The American Journal of Cardiology, 1994
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarctionJACC, 1992
- Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarctionJACC, 1992
- Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activatorJACC, 1989
- Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.Circulation, 1988
- AN EVALUATION OF THE EUGLOBULIN METHOD FOR THE DETERMINATION OF FIBRINOLYSISJournal of Clinical Pathology, 1959